Understanding KYPROLIS® (carfilzomib) for Injection

Understanding KYPROLIS® (carfilzomib) injection discusses a proteasome inhibitor approved by the FDA for the treatment of patients with relapsed or refractory myeloma who have received one or more prior lines of therapy. Kyprolis can be administered as part of several different dosing regimens, including in combination with an immunomodulatory agent or with a monoclonal antibody. In addition, Kyprolis is being studied in numerous clinical trials throughout the myeloma disease course.

Update 4/1/2022


Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.